Early antibody therapy can induce long-lasting immunity to SHIV

Yoshiaki Nishimura, Rajeev Gautam, Tae-Wook Chun, Reza Sadjadpour, Kathryn E. Foulds, Masashi Shingai, Florian Klein, Anna Gazumyan, Jovana Golijanin, Mitzi Donaldson, Olivia K. Donau, Ronald J. Plishka, Alicia Buckler-White, Michael S. Seaman, Jeffrey D. Lifson, Richard A. Koup, Anthony S. Fauci, Michel C. Nussenzweig () and Malcolm A. Martin ()
Additional contact information
Yoshiaki Nishimura: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Rajeev Gautam: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Tae-Wook Chun: Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Reza Sadjadpour: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Kathryn E. Foulds: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Masashi Shingai: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Florian Klein: Institute of Virology, University of Cologne
Anna Gazumyan: Laboratory of Molecular Immunology, The Rockefeller University
Jovana Golijanin: Laboratory of Molecular Immunology, The Rockefeller University
Mitzi Donaldson: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Olivia K. Donau: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Ronald J. Plishka: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Alicia Buckler-White: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Michael S. Seaman: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center
Jeffrey D. Lifson: AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research
Richard A. Koup: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Anthony S. Fauci: Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Michel C. Nussenzweig: Laboratory of Molecular Immunology, The Rockefeller University
Malcolm A. Martin: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Nature, 2017, vol. 543, issue 7646, 559-563

Abstract: Early administration of broadly neutralizing antibodies in a macaque SHIV infection model is associated with very low levels of persistent viraemia, which leads to the establishment of T-cell immunity and resultant long-term infection control.

Date: 2017
References: Add references at CitEc
Citations: View citations in EconPapers (6)

Downloads: (external link)
https://www.nature.com/articles/nature21435 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:543:y:2017:i:7646:d:10.1038_nature21435

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature21435

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().